The FDA's decision to open a public docket signals potential vulnerability in the NCE exclusivity determination. Monitor the November 23 comment deadline and any FDA reconsideration; a reversal would open the door to generic competition years earlier than expected.
Price Chart
Executive Summary
Phathom Pharmaceuticals disclosed that the FDA has opened a public docket to solicit comments on legal and regulatory issues raised by ANDA filer BDR Pharmaceuticals in litigation challenging the FDA's June 2025 decision granting VOQUEZNA 10 years of NCE exclusivity through May 2032. A second ANDA filer, Saba Ilac, has moved to consolidate its related case with BDR's. The exclusivity remains in effect, but the FDA could reconsider its decision based on public comments or the litigation outcome.
Key Facts
- FDA established public docket FDA-2026-N-13038 to solicit comment on issues raised by ANDA filer BDR Pharmaceuticals in litigation challenging the FDA's June 6, 2025 decision granting Phathom's Citizen Petition for VOQUEZNA NCE exclusivity.
- VOQUEZNA currently benefits from 10 years of NCE exclusivity through May 3, 2032.
- Deadline for public comments is November 23, 2026.
- A second ANDA filer, Saba Ilac Sanayii Ve Ticaret AS, has filed a notice in the BDR litigation claiming a pending related case and intends to move to consolidate.
- Phathom states it will submit comments and intervene in litigation to defend the exclusivity.
Financial Impact
Loss of NCE exclusivity would permit FDA to approve generic ANDAs for VOQUEZNA earlier than May 2032, potentially eliminating Phathom's U.S. market exclusivity for its only marketed product. No financial figures for VOQUEZNA revenue or potential generic erosion are provided in the filing.
Risk Factors
- FDA may reconsider, modify, or reverse its prior NCE exclusivity decision based on public comments or litigation outcome.
- BDR or Saba Ilac may succeed in court, reducing exclusivity period and allowing earlier ANDA approvals.
- Litigation may be lengthy, costly, and distracting to management.
- Loss of exclusivity would expose VOQUEZNA to generic competition, materially impacting revenue.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-430977 |
| Document: 0001193125-26-430977-index-headers.html | 0001193125-26-430977 |
| Document: 0001193125-26-430977-index.html | 0001193125-26-430977 |
| Document: 0001193125-26-430977.txt | 0001193125-26-430977 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 8-K | $5.50 | awaiting T+60 | — | $5.93 (−7.82%) |
Oct 23, 2026 3d ago | 8-K | $6.72 | awaiting T+60 | — | $5.93 (+11.76%) |
Oct 19, 2026 8d ago | Press Release | $7.01 | awaiting T+60 | — | $5.93 (−15.41%) |
Sep 29, 2026 27d ago | 8-K | $7.30 | awaiting T+60 | — | $5.93 (−18.77%) |
Jul 30, 2026 12w ago | 8-K | $9.03 $5.74 | ▼ −36.43% | ▼ −38.90% | $5.93 (−34.33%) |
Jul 30, 2026 12w ago | Press Release | $9.03 $5.74 | ▲ +36.43% | ▲ +38.90% | $5.93 (+34.33%) |
Jul 20, 2026 14w ago | Press Release | $10.65 | awaiting T+60 | — | $5.93 (−44.32%) |
May 20, 2026 22w ago | Press Release | $11.87 $9.58 | ▼ −19.29% | ▼ −24.30% | $5.93 (−50.04%) |
May 1, 2026 25w ago | Press Release | $12.01 $11.66 | ▼ −2.91% | ▼ −5.98% | $5.93 (−50.62%) |
Apr 30, 2026 25w ago | Press Release | $11.20 $11.95 | ▲ +6.70% | ▲ +3.59% | $5.93 (−47.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers